The study, published in The Journal of Pediatrics, showed that the aluminum used as vaccine adjuvants also does not increase the risk of the neurological condition.
A Phase 1 clinical trial of a novel Nipah virus vaccine has found it to be safe and capable of generating a strong immune response, raising hopes for preventing the deadly infection